Stock Insiders: PharmAust’s subsidiary Epichem generates $3.5m in sales in FY2022

Stock Insiders is a podcast series focussed on investing hosted by renowned business journalist Oriel Morrison.

In this episode Oriel talks to Anusha Aubert, head of investor relations at PharmAust (ASX:PAA).

The company is a clinical-stage developer of therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA’s subsidiary, Epichem, a highly successful contract medicinal chemistry company which generated $3.4 million in sales of goods & services in FY 2022.

The company recently made news receiving recognition for its innovative clinical research, backed by a Research and Development Tax Incentive (RDTI) for the 2022 tax year.

To hear more, click below